Chimeric oncolytic herpesvirus that stimulates an antitumor immune response
AssigneeResearch Institute At Nationwide Children's Hospital
InventorsKevin A. Cassady, Justin C. Roth
Life of this patent
Estimating the term…
Abstract
A chimeric oncolytic virus is described that includes a herpesvirus having a modified nucleic acid sequence, including a modification of the herpesvirus gamma (1)34.5 gene (γ134.5) or a nucleic acid with at least about 70% homology to the γ134.5 gene that reduces its expression; a second viral nucleic acid sequence encoding a PKR evasion protein that does not cause virulence; and a third nucleic acid sequence encoding a tumor-associated antigen. Methods of using the chimeric oncolytic virus to treat subjects having cancer, or to vaccinate subjects at risk of developing cancer, are also described.
Claims32
A chimeric oncolytic virus, comprising:
- a herpesvirus having a modified nucleic acid sequence, comprising:
- a modification of the herpesvirus gamma (1)34.5 gene (γ134.5) or a nucleic acid with at least about 70% homology to the γ134.5 gene that reduces its expression;
- a second viral nucleic acid sequence encoding a PKR evasion protein that does not cause virulence;
- and
- a third nucleic acid sequence encoding a tumor-associated antigen.
A method of treating cancer by in a subject by contacting a cancer cell of the subject with a chimeric oncolytic virus, comprising:
- a herpesvirus having a modified nucleic acid sequence, comprising:
- a modification of the herpesvirus gamma (1)34.5 gene (γ134.5) or a nucleic acid with at least about 70% homology to the γ134.5 gene that reduces its expression;
- a second viral nucleic acid sequence encoding a PKR evasion protein that does not cause virulence;
- and
- a third nucleic acid sequence encoding a tumor-associated antigen.
A method of immunizing a subject against cancer, comprising administering to the subject a chimeric oncolytic virus, comprising:
- a herpesvirus having a modified nucleic acid sequence, comprising:
- a modification of the herpesvirus gamma (1)34.5 gene (γ134.5) or a nucleic acid with at least about 70% homology to the γ134.5 gene that reduces its expression;
- a second viral nucleic acid sequence encoding a PKR evasion protein that does not cause virulence;
- and
- a third nucleic acid sequence encoding a tumor-associated antigen wherein the chimeric oncolytic virus is administered under conditions effective to immunize the subject against cancer.
Dependencies are inferred from the claim text.